Siti Internazionali
Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.
Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.
In evidenza
In evidenza
Temi caldi
Comunicato stampa
Novotech Releases Hepatitis B Global Clinical Trial Landscape Report 2025
Comunicato stampa
Responsabilità editoriale di Business Wire
Global Insights into Hepatitis B Clinical Research: Novotech Releases 2025 Report
Comunicato stampa - Responsabilità editoriale di Business Wire
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released its latest disease report: Hepatitis B - Global Clinical Trial Landscape (2025) . The report provides a comprehensive analysis of global trends, challenges, and emerging opportunities in the Hepatitis B clinical research ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306591902/en/
The report leverages Novotech’s extensive experience and offers valuable insights for biotech companies, healthcare professionals, and stakeholders engaged in Hepatitis B research, featuring:
- Epidemiology Overview : Insights into the global burden of Hepatitis B, with a detailed focus on high-prevalence regions including Asia-Pacific and Africa.
- Clinical Trial Landscape : Analysis of over 100 industry-sponsored trials globally, with Asia-Pacific leading in trial density and innovation. Novotech has managed 90 trials in the region, with Australia hosting 79. Additional contributions from Hong Kong, Taiwan, New Zealand, South Korea, and Thailand reinforce the region’s role in advancing Hepatitis B research.
- Drug Pipeline Innovations : Exploration of advanced therapeutic modalities, including RNA-based therapies, antisense oligonucleotides, monoclonal antibodies, and therapeutic vaccines.
- Biomarkers and Clinical Endpoints : A guide to emerging biomarkers such as HBV RNA and HBcrAg, and their role in optimizing clinical outcomes and trial designs.
The report highlights a 31.95% CAGR in Hepatitis B trials from 2020 to 2024, driven by advances in small molecules, siRNA therapies, and therapeutic vaccines. Novotech is the global leader in hepatitis B research, having supported 90 Hepatitis B trials and counting, initiating 340+ sites and enrolling 5,000+ participants across all trial phases, including 65 Phase I and 25 Phase II studies. With experience in diverse therapeutic modalities such as small molecules, antisense RNAi oligonucleotides, monoclonal antibodies, vaccines, proteins, and peptides.
The Hepatitis B - Global Clinical Trial Landscape (2025) report is now available for download. Gain actionable insights to guide your clinical development strategies and optimize trial execution.
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306591902/en/
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
Permalink: http://www.businesswire.com/news/home/20250306591902/en
Comunicato stampa - Responsabilità editoriale di Business Wire
Ultima ora